Previous 10 | Next 10 |
Introduction Sangamo Therapeutics ( SGMO ) is a clinical-stage biotech company focusing on the research and development of genomic medicine across 4 distinct technology platforms: gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. Sangamo is best-known for...
Introduction Since my last article on Iovance Biotherapeutics about 4 months, its share price has taken on a wild ride and went up by more than 75% to reach a new all-time high of $38.92, largely due to a report from Bloomberg that the company was exploring a sale. It is worth noting tha...
BTIG is out with its Highest Conviction Ideas for the next 12 months... Some of its top ideas follow, starting with consumer stocks: More news on: Chipotle Mexican Grill, Inc., Papa John's International, Inc., D.R. Horton, Inc., Notable Calls, Read more ...
Introduction Celyad ( CYAD ) is a clinical-stage biopharmaceutical company, focusing on the development of CAR-T cell therapy for treating cancers. The company has both autologous and allogeneic technological platforms for CAR-T and has 2 international partnerships with Novartis and Horizo...
Following Series of US and European Patent Grants, Cellectis Strengthens its Intellectual Property on CRISPR-Edited T-cell Therapies Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused o...
Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report the fourth quarter 2019 and ...
Introduction Precision BioSciences ( DTIL ) is a genome editing company dedicated to improving life through their proprietary genome editing platform (“ARCUS”), where they are developing product candidates in three high-value areas: allogeneic CAR T immunotherapy, in vivo g...
Cellectis grants additional rights to Servier to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including ALLO-501A Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biop...
The CAR-T landscape is replete with different permutations of the technology that are often arcane and difficult to grasp for even seasoned investors. Each formulation has its own advantages and disadvantages critical to understand in order to get a decent hold on a company’s long term ...
This article was highlighted for PRO+ subscribers, Seeking Alpha's service for professional investors. Find out how you can get the best content on Seeking Alpha here . The CAR-T space got a bit ahead of itself over the last 3-4 years. Now that the buzz has subsided after two big buyouts ...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...